About Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

ARWR Key Statistics

ARWR Price Performance

Arrowhead Pharmaceuticals, Inc. stock has returned -2.30% over the past day, +0.33% over the past week, +1.96% over the past month, and -2.97% over the past three months. The stock trades between a 52-week low of $9.57 and a high of $76.76.

ARWR Financial Fundamentals

Arrowhead Pharmaceuticals, Inc. reports a return on equity (ROE) of +65.14%, operating margin of +27.55%, profit margin of +1853.97%, and revenue growth of +10461.30%. The debt-to-equity ratio is 1.21. Current ratio stands at 3.38.

ARWR Earnings

Arrowhead Pharmaceuticals, Inc.'s next earnings report is expected on 2026-05-11 (67 days away). The company has a +0.50% earnings beat rate with an average surprise of +363.21%. Earnings consistency is rated as "medium".

ARWR Ownership

Institutional investors hold approximately +0.84% of ARWR shares across 10 institutions. Insider ownership is +0.04%. Insider sentiment is "bearish".

ARWR Short Interest

ARWR has a short interest of +5.11% of float with a short ratio (days to cover) of 5.5.

ARWR AI Analysis Signal

iGotFomo's AI-powered signal engine rates ARWR as "HOLD" with LOW confidence (score: 28/100). 4 signals are bullish, 5 are bearish, and 4 are neutral.